InvestSMART

Resonance Health Limited (ASX:RHT)

ALERT: Price-sensitive ASX Announcement for RHT
Current share price for RHT : $0.048 0 (0%)+
Announcement
Release
5 May 2026 9:58AM
Price at Release
$0.048
Full Release
download
Summary
Resonance Health Limited has upgraded its profit guidance for the financial year ending June 30, 2026. The company anticipates a 30% increase in the underlying EBITDA to approximately $2.6 million, driven by strong operational performance, cost efficiencies, and contributions from higher-margin activities. Despite a slight reduction in revenue expectations to $16 million due to revenue recognition timing, the company expects improved profitability through operational efficiencies and margin expansion. Resonance Health is focusing on its clinical trial services and Software-as-Medical Devices (SaMD), aiming for significant revenue and margin growth in the medium term.
Key Points
  • FY26 underlying EBITDA guidance upgraded to $2.6 million.
  • 30% increase in underlying EBITDA compared to previous guidance.
  • FY26 revenue expected to be approximately $16 million.
  • Strong operational performance and cost efficiencies drive EBITDA growth.
  • Focus on clinical trial services and SaMD for higher-margin opportunities.
  • Automation and workflow improvements support profitability.
  • Medium-term goal to scale revenue towards $30 million.
  • Continued investment in AI and automation for scalability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.